A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

~30 mi. (Ravensburg, Germany, +144 more cities)

GSK Investigational Site

Endometrial Carcinoma

carboplatin, +3 more drugs

chemotherapy, +2 more types

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

~30 mi. (Ravensburg, Germany, +170 more cities)

Novartis Investigative Site

ER Negative, +4 more biomarkers

Breast Carcinoma

alpelisib, +1 more drug

chemotherapy, +1 more type

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)

~30 mi. (Ravensburg, Germany, +76 more cities)

Onkologie Ravensburg ( Site 1104)

Non-Small Cell Lung Carcinoma

docetaxel, +1 more drug

chemotherapy, +1 more type

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

~38 mi. (Eßlingen, Germany, +145 more cities)

Klinikum Esslingen-Klinik für Kardiologie und Pneumologie ( Site 1208)

Non-Small Cell Lung Carcinoma

pembrolizumab, +1 more drug

immunotherapy, +2 more types

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

~42 mi. (Reutlingen, Germany, +94 more cities)

Klinikum am Steinenberg

HER2 Negative

Breast Carcinoma

sacituzumab govitecan

chemotherapy, +1 more type

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~47 mi. (Tübingen, Germany, +226 more cities)

Universitaetsklinik fuer Urologie ( Site 0307)

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

~47 mi. (Tübingen, Germany, +93 more cities)

Universitaetsklinik fuer Urologie ( Site 0501)

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

~47 mi. (Tübingen, Germany, +159 more cities)

Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0502)

Superficial Bladder Urothelial Carcinoma

cisplatin, +2 more drugs

chemotherapy, +1 more type

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

~47 mi. (Tübingen, Germany, +163 more cities)

Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0549)

Bladder Urothelial Carcinoma

cystectomy, +2 more drugs

chemotherapy, +3 more types

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

~47 mi. (Tübingen, Germany, +150 more cities)

Universitaetsklinikum Tuebingen - Medizinische Klinik ( Site 0401)

Head and Neck Squamous Cell Carcinoma

cisplatin, +2 more drugs

chemotherapy, +2 more types

Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

~47 mi. (Tübingen, Germany, +137 more cities)

Universitaetsklinikum Tuebingen ( Site 0409)

Skin Squamous Cell Carcinoma

pembrolizumab

immunotherapy

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)

~47 mi. (Tübingen, Germany, +127 more cities)

Universitaetsklinikum Tuebingen ( Site 2108)

Hypopharyngeal Squamous Cell Carcinoma, +3 more conditions

lenvatinib, +1 more drug

immunotherapy, +1 more type